Pembrolizumab: Phase II started

Cancer Treatment Centers of America began the Phase II portion of the open-label, U.S. Phase Ib/II PembroPlus trial to evaluate 2 mg/kg IV Keytruda from Merck every 3 weeks in combination with gemcitabine, docetaxel, Abraxane nab-paclitaxel, vinorelbine, irinotecan and/or liposomal doxorubicin in up to 140 patients. The Phase II portion will enroll patients with advanced small cell lung cancer (SCLC), pancreatic cancer and connective-tissue cancers, including breast cancer. ...